img

Global Prophylactic HIV Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Prophylactic HIV Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases.
The global Prophylactic HIV Drug market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Prophylactic HIV Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Prophylactic HIV Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Prophylactic HIV Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Prophylactic HIV Drug include Gilead Sciences, Merck, Mylan, Cipla, Bristol-Myers Squibb and Roche, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Prophylactic HIV Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Prophylactic HIV Drug by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Prophylactic HIV Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Prophylactic HIV Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Gilead Sciences
Merck
Mylan
Cipla
Bristol-Myers Squibb
Roche
By Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
By Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Prophylactic HIV Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prophylactic HIV Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Prophylactic HIV Drug Definition
1.2 Market by Type
1.2.1 Global Prophylactic HIV Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Integrase Inhibitor
1.3 Market Segment by Application
1.3.1 Global Prophylactic HIV Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Prophylactic HIV Drug Sales
2.1 Global Prophylactic HIV Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Prophylactic HIV Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Prophylactic HIV Drug Revenue by Region
2.3.1 Global Prophylactic HIV Drug Revenue by Region (2018-2024)
2.3.2 Global Prophylactic HIV Drug Revenue by Region (2024-2034)
2.4 Global Prophylactic HIV Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Prophylactic HIV Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Prophylactic HIV Drug Sales Quantity by Region
2.6.1 Global Prophylactic HIV Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Prophylactic HIV Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Prophylactic HIV Drug Sales Quantity by Manufacturers
3.1.1 Global Prophylactic HIV Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Prophylactic HIV Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Prophylactic HIV Drug Sales in 2022
3.2 Global Prophylactic HIV Drug Revenue by Manufacturers
3.2.1 Global Prophylactic HIV Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Prophylactic HIV Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Prophylactic HIV Drug Revenue in 2022
3.3 Global Prophylactic HIV Drug Sales Price by Manufacturers
3.4 Global Key Players of Prophylactic HIV Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Prophylactic HIV Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Prophylactic HIV Drug, Product Offered and Application
3.8 Global Key Manufacturers of Prophylactic HIV Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Prophylactic HIV Drug Sales Quantity by Type
4.1.1 Global Prophylactic HIV Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Prophylactic HIV Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Prophylactic HIV Drug Revenue by Type
4.2.1 Global Prophylactic HIV Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
4.3 Global Prophylactic HIV Drug Price by Type
4.3.1 Global Prophylactic HIV Drug Price by Type (2018-2024)
4.3.2 Global Prophylactic HIV Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Prophylactic HIV Drug Sales Quantity by Application
5.1.1 Global Prophylactic HIV Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Prophylactic HIV Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Prophylactic HIV Drug Revenue by Application
5.2.1 Global Prophylactic HIV Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
5.3 Global Prophylactic HIV Drug Price by Application
5.3.1 Global Prophylactic HIV Drug Price by Application (2018-2024)
5.3.2 Global Prophylactic HIV Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Prophylactic HIV Drug Sales by Company
6.1.1 North America Prophylactic HIV Drug Revenue by Company (2018-2024)
6.1.2 North America Prophylactic HIV Drug Sales Quantity by Company (2018-2024)
6.2 North America Prophylactic HIV Drug Market Size by Type
6.2.1 North America Prophylactic HIV Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Prophylactic HIV Drug Revenue by Type (2018-2034)
6.3 North America Prophylactic HIV Drug Market Size by Application
6.3.1 North America Prophylactic HIV Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Prophylactic HIV Drug Revenue by Application (2018-2034)
6.4 North America Prophylactic HIV Drug Market Size by Country
6.4.1 North America Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Prophylactic HIV Drug Revenue by Country (2018-2034)
6.4.3 North America Prophylactic HIV Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Prophylactic HIV Drug Sales by Company
7.1.1 Europe Prophylactic HIV Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Prophylactic HIV Drug Revenue by Company (2018-2024)
7.2 Europe Prophylactic HIV Drug Market Size by Type
7.2.1 Europe Prophylactic HIV Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Prophylactic HIV Drug Revenue by Type (2018-2034)
7.3 Europe Prophylactic HIV Drug Market Size by Application
7.3.1 Europe Prophylactic HIV Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Prophylactic HIV Drug Revenue by Application (2018-2034)
7.4 Europe Prophylactic HIV Drug Market Size by Country
7.4.1 Europe Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Prophylactic HIV Drug Revenue by Country (2018-2034)
7.4.3 Europe Prophylactic HIV Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Prophylactic HIV Drug Sales by Company
8.1.1 China Prophylactic HIV Drug Sales Quantity by Company (2018-2024)
8.1.2 China Prophylactic HIV Drug Revenue by Company (2018-2024)
8.2 China Prophylactic HIV Drug Market Size by Type
8.2.1 China Prophylactic HIV Drug Sales Quantity by Type (2018-2034)
8.2.2 China Prophylactic HIV Drug Revenue by Type (2018-2034)
8.3 China Prophylactic HIV Drug Market Size by Application
8.3.1 China Prophylactic HIV Drug Sales Quantity by Application (2018-2034)
8.3.2 China Prophylactic HIV Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Prophylactic HIV Drug Sales by Company
9.1.1 APAC Prophylactic HIV Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Prophylactic HIV Drug Revenue by Company (2018-2024)
9.2 APAC Prophylactic HIV Drug Market Size by Type
9.2.1 APAC Prophylactic HIV Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Prophylactic HIV Drug Revenue by Type (2018-2034)
9.3 APAC Prophylactic HIV Drug Market Size by Application
9.3.1 APAC Prophylactic HIV Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Prophylactic HIV Drug Revenue by Application (2018-2034)
9.4 APAC Prophylactic HIV Drug Market Size by Region
9.4.1 APAC Prophylactic HIV Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Prophylactic HIV Drug Revenue by Region (2018-2034)
9.4.3 APAC Prophylactic HIV Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Prophylactic HIV Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Prophylactic HIV Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Prophylactic HIV Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Prophylactic HIV Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Information
11.1.2 Gilead Sciences Overview
11.1.3 Gilead Sciences Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Gilead Sciences Prophylactic HIV Drug Products and Services
11.1.5 Gilead Sciences Prophylactic HIV Drug SWOT Analysis
11.1.6 Gilead Sciences Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Merck Prophylactic HIV Drug Products and Services
11.2.5 Merck Prophylactic HIV Drug SWOT Analysis
11.2.6 Merck Recent Developments
11.3 Mylan
11.3.1 Mylan Company Information
11.3.2 Mylan Overview
11.3.3 Mylan Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Mylan Prophylactic HIV Drug Products and Services
11.3.5 Mylan Prophylactic HIV Drug SWOT Analysis
11.3.6 Mylan Recent Developments
11.4 Cipla
11.4.1 Cipla Company Information
11.4.2 Cipla Overview
11.4.3 Cipla Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Cipla Prophylactic HIV Drug Products and Services
11.4.5 Cipla Prophylactic HIV Drug SWOT Analysis
11.4.6 Cipla Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Information
11.5.2 Bristol-Myers Squibb Overview
11.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Bristol-Myers Squibb Prophylactic HIV Drug Products and Services
11.5.5 Bristol-Myers Squibb Prophylactic HIV Drug SWOT Analysis
11.5.6 Bristol-Myers Squibb Recent Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Overview
11.6.3 Roche Prophylactic HIV Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Roche Prophylactic HIV Drug Products and Services
11.6.5 Roche Prophylactic HIV Drug SWOT Analysis
11.6.6 Roche Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Prophylactic HIV Drug Value Chain Analysis
12.2 Prophylactic HIV Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Prophylactic HIV Drug Production Mode & Process
12.4 Prophylactic HIV Drug Sales and Marketing
12.4.1 Prophylactic HIV Drug Sales Channels
12.4.2 Prophylactic HIV Drug Distributors
12.5 Prophylactic HIV Drug Customers
13 Market Dynamics
13.1 Prophylactic HIV Drug Industry Trends
13.2 Prophylactic HIV Drug Market Drivers
13.3 Prophylactic HIV Drug Market Challenges
13.4 Prophylactic HIV Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Table 3. Major Manufacturers of Integrase Inhibitor
Table 4. Global Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Prophylactic HIV Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Prophylactic HIV Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Prophylactic HIV Drug Revenue Market Share by Region (2018-2024)
Table 8. Global Prophylactic HIV Drug Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Prophylactic HIV Drug Revenue Market Share by Region (2024-2034)
Table 10. Global Prophylactic HIV Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Prophylactic HIV Drug Sales by Region (2018-2024) & (K Units)
Table 12. Global Prophylactic HIV Drug Sales Market Share by Region (2018-2024)
Table 13. Global Prophylactic HIV Drug Sales by Region (2024-2034) & (K Units)
Table 14. Global Prophylactic HIV Drug Sales Market Share by Region (2024-2034)
Table 15. Global Prophylactic HIV Drug Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Prophylactic HIV Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Prophylactic HIV Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Prophylactic HIV Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Prophylactic HIV Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Prophylactic HIV Drug, Industry Ranking, 2021 VS 2022
Table 21. Global Prophylactic HIV Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Prophylactic HIV Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Prophylactic HIV Drug as of 2022)
Table 23. Global Key Manufacturers of Prophylactic HIV Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Prophylactic HIV Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Prophylactic HIV Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Prophylactic HIV Drug Sales Quantity Share by Type (2018-2024)
Table 30. Global Prophylactic HIV Drug Sales Quantity Share by Type (2024-2034)
Table 31. Global Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Prophylactic HIV Drug Revenue Share by Type (2018-2024)
Table 34. Global Prophylactic HIV Drug Revenue Share by Type (2024-2034)
Table 35. Prophylactic HIV Drug Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Prophylactic HIV Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Prophylactic HIV Drug Sales Quantity Share by Application (2018-2024)
Table 40. Global Prophylactic HIV Drug Sales Quantity Share by Application (2024-2034)
Table 41. Global Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Prophylactic HIV Drug Revenue Share by Application (2018-2024)
Table 44. Global Prophylactic HIV Drug Revenue Share by Application (2024-2034)
Table 45. Prophylactic HIV Drug Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Prophylactic HIV Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Prophylactic HIV Drug Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Prophylactic HIV Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Prophylactic HIV Drug Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Prophylactic HIV Drug Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Prophylactic HIV Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Prophylactic HIV Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Prophylactic HIV Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Prophylactic HIV Drug Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Prophylactic HIV Drug Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Prophylactic HIV Drug Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Prophylactic HIV Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Prophylactic HIV Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Prophylactic HIV Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Prophylactic HIV Drug Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Prophylactic HIV Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Prophylactic HIV Drug Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Prophylactic HIV Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Prophylactic HIV Drug Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Prophylactic HIV Drug Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Prophylactic HIV Drug Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Prophylactic HIV Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Gilead Sciences Company Information
Table 118. Gilead Sciences Description and Overview
Table 119. Gilead Sciences Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Gilead Sciences Prophylactic HIV Drug Product and Services
Table 121. Gilead Sciences Prophylactic HIV Drug SWOT Analysis
Table 122. Gilead Sciences Recent Developments
Table 123. Merck Company Information
Table 124. Merck Description and Overview
Table 125. Merck Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Merck Prophylactic HIV Drug Product and Services
Table 127. Merck Prophylactic HIV Drug SWOT Analysis
Table 128. Merck Recent Developments
Table 129. Mylan Company Information
Table 130. Mylan Description and Overview
Table 131. Mylan Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. Mylan Prophylactic HIV Drug Product and Services
Table 133. Mylan Prophylactic HIV Drug SWOT Analysis
Table 134. Mylan Recent Developments
Table 135. Cipla Company Information
Table 136. Cipla Description and Overview
Table 137. Cipla Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. Cipla Prophylactic HIV Drug Product and Services
Table 139. Cipla Prophylactic HIV Drug SWOT Analysis
Table 140. Cipla Recent Developments
Table 141. Bristol-Myers Squibb Company Information
Table 142. Bristol-Myers Squibb Description and Overview
Table 143. Bristol-Myers Squibb Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. Bristol-Myers Squibb Prophylactic HIV Drug Product and Services
Table 145. Bristol-Myers Squibb Prophylactic HIV Drug SWOT Analysis
Table 146. Bristol-Myers Squibb Recent Developments
Table 147. Roche Company Information
Table 148. Roche Description and Overview
Table 149. Roche Prophylactic HIV Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Roche Prophylactic HIV Drug Product and Services
Table 151. Roche Prophylactic HIV Drug SWOT Analysis
Table 152. Roche Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Prophylactic HIV Drug Distributors List
Table 156. Prophylactic HIV Drug Customers List
Table 157. Prophylactic HIV Drug Market Trends
Table 158. Prophylactic HIV Drug Market Drivers
Table 159. Prophylactic HIV Drug Market Challenges
Table 160. Prophylactic HIV Drug Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Prophylactic HIV Drug Product Picture
Figure 2. Global Prophylactic HIV Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Prophylactic HIV Drug Market Share by Type in 2022 & 2034
Figure 4. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Product Picture
Figure 5. Integrase Inhibitor Product Picture
Figure 6. Global Prophylactic HIV Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Prophylactic HIV Drug Market Share by Application in 2022 & 2034
Figure 8. Hospital Pharmacy
Figure 9. Retail Pharmacy
Figure 10. Online Pharmacy
Figure 11. Prophylactic HIV Drug Report Years Considered
Figure 12. Global Prophylactic HIV Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Prophylactic HIV Drug Revenue 2018-2034 (US$ Million)
Figure 14. Global Prophylactic HIV Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Prophylactic HIV Drug Sales Quantity 2018-2034 (K Units)
Figure 16. Global Prophylactic HIV Drug Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Prophylactic HIV Drug Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Prophylactic HIV Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Prophylactic HIV Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Prophylactic HIV Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Prophylactic HIV Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Prophylactic HIV Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Prophylactic HIV Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Prophylactic HIV Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Prophylactic HIV Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Prophylactic HIV Drug Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Prophylactic HIV Drug Revenue in 2022
Figure 30. Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 33. Global Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 35. North America Prophylactic HIV Drug Revenue Market Share by Company in 2022
Figure 36. North America Prophylactic HIV Drug Sales Quantity Market Share by Company in 2022
Figure 37. North America Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 39. North America Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 41. North America Prophylactic HIV Drug Revenue Share by Country (2018-2034)
Figure 42. North America Prophylactic HIV Drug Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Prophylactic HIV Drug Sales Quantity Market Share by Company in 2022
Figure 46. Europe Prophylactic HIV Drug Revenue Market Share by Company in 2022
Figure 47. Europe Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 49. Europe Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 51. Europe Prophylactic HIV Drug Revenue Share by Country (2018-2034)
Figure 52. Europe Prophylactic HIV Drug Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 54. France Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 58. China Prophylactic HIV Drug Sales Quantity Market Share by Company in 2022
Figure 59. China Prophylactic HIV Drug Revenue Market Share by Company in 2022
Figure 60. China Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 62. China Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 64. APAC Prophylactic HIV Drug Sales Quantity Market Share by Company in 2022
Figure 65. APAC Prophylactic HIV Drug Revenue Market Share by Company in 2022
Figure 66. APAC Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 68. APAC Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 70. APAC Prophylactic HIV Drug Revenue Share by Region (2018-2034)
Figure 71. APAC Prophylactic HIV Drug Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 76. India Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Prophylactic HIV Drug Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Prophylactic HIV Drug Revenue Share by Country (2018-2034)
Figure 85. Brazil Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Prophylactic HIV Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Prophylactic HIV Drug Value Chain
Figure 91. Prophylactic HIV Drug Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries